MK-677 (ibutamoren)
MK-677, or ibutamoren, is a pill that raises growth hormone. It is not a peptide. It has real human trials, and they are the reason for caution: a small gain in lean mass with no gain in strength, higher blood sugar, and one trial stopped early over heart failure.
- Legal lane: not FDA-approved. On the FDA's list of substances that may present significant safety risks in compounding.
- Evidence grade: B. Real human trials, with mixed and partly negative results.
- Form: taken by mouth
- Sport: prohibited at all times
What it is
Ibutamoren is a small molecule that imitates ghrelin at the receptor that triggers growth hormone release. Unlike the injectable growth hormone peptides, it works when swallowed. Merck developed it in the 1990s and stopped. Another company has since studied it for growth hormone deficiency in children.
What the evidence shows
- Healthy older adults: a two-year trial in 65 adults aged 60 to 81 found that 25 mg a day raised growth hormone and IGF-1 to young-adult levels. After 12 months, fat-free mass was up 1.1 kg against a 0.5 kg loss on placebo. Strength and physical function did not improve, and fasting blood sugar rose.
- Hip fracture recovery: a trial in 123 older patients was stopped early because of a heart failure signal, reported as about 6.5% of patients on the drug against 1.7% on placebo. The authors concluded it had an unfavorable safety profile in that group, and most measures of function did not improve.
- Alzheimer's disease: a large trial did not slow the disease.
The pattern across the trials is consistent: the hormone numbers move, and the outcomes people care about mostly do not.
Legal status
- MK-677 is not FDA-approved for any use.
- The FDA lists ibutamoren among bulk substances that may present significant safety risks in compounding, citing the heart failure finding. It is not eligible for routine pharmacy compounding.
- It is not a dietary supplement ingredient, although it is sold online as one and as a "research chemical".
Reported dosing
No approved dose exists.
The dose used in the main trials was 25 mg once a day by mouth, in monitored studies of older adults and patients. That is what was tested. It is not a recommendation, and the hip fracture trial at that dose was the one stopped for safety.
Safety
- Heart failure: the signal that stopped the hip fracture trial. Most relevant to older people and anyone with heart disease.
- Blood sugar: fasting glucose rose in trials, and insulin sensitivity fell.
- Common effects in trials: increased appetite, swelling in the legs and muscle aches.
- Long-term safety: not established.
- Quality: products sold online have no verified contents.
Common questions
Is MK-677 a peptide?
No. It is a small-molecule drug taken by mouth. It is sold alongside peptides because it raises growth hormone.
Is MK-677 legal?
It is not FDA-approved, and the FDA lists it among substances that may present significant safety risks in compounding.
Does MK-677 build muscle?
In the main trial, fat-free mass rose by 1.1 kg over 12 months, but strength and physical function did not improve.
Why was an MK-677 trial stopped?
A trial in hip fracture patients was ended early because of a heart failure signal in patients taking the drug.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.
Sources
- Nass et al., 2008: two-year trial of MK-677 in healthy older adults, Annals of Internal Medicine (PubMed)
- Adunsky et al., 2011: MK-0677 in patients recovering from hip fracture, Phase 2b (PubMed)
- Tel Aviv University record of the hip fracture trial: early termination for a heart failure signal
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks
- Superpower: summary of the MK-677 trials, including the Alzheimer's trial and anti-doping status